Alamar Biosciences

Alamar Biosciences is a privately held life sciences company dedicated to transforming the field of proteomics for the early detection of cancer and other diseases. The company’s two proprietary technology platforms, NULISA™ and Attobody™, work seamlessly with the latest advances in genomics to achieve single-digit attomolar detection sensitivity, far surpassing the most sensitive protein detection technologies currently on the market. This has the potential to unlock the promise of the human plasma proteome, enabling the early detection and prevention of common diseases through a new wave of biomarkers, thereby revolutionizing healthcare.